source
- Ivonescimab cuts death risk by 34% in Chinese trial for squamous NSCLCData presented at the American Society of Clinical Oncology showed that ivonescimab, a bispecific antibody combining two established cancer drugs, lowered the risk of death by 34% compared with sta…
- Phase 3 trial shows pre- and post-surgery hormone therapy improves outcomes for high-risk prostate cancerA phase 3 study called PROTEUS evaluated high‑risk, early‑stage prostate cancer patients who were scheduled for surgery. The trial compared a regimen that gave two hormone therapies before and afte…